MindMed is utilizing MDMA with LSD, to endeavour to reduce side effects of LSD-assisted therapy.
MindMed is utilizing MDMA with LSD, to endeavour to reduce side effects of LSD-assisted therapy.
Field Trip Psychedelics completes its qualifying transaction and definitive agreement with RTO partner.
Wall Street and Silicon Valley investors recently piled into a $30-million psychedelics fund-raising initiative.
Wuhan General (soon to be M2Bio Sciences) has released a corporate update on its psychedelics and cannabis operations.
IntelGenX enters into agreement with ATAI Life Sciences to develop novel formulations of pharmaceutical-grade psychedelics.
Global Trac Solutions is developing a media partnership with Microdose.
Mydecine is ready to start supplying GMP-quality psilocybin to advance psychedelics R&D.
Psychedelic drug therapies continue to win over new supporters. But the clock is ticking with our Mental Health Crisis...
Field Trip adds a ketamine-assisted psychotherapy clinic to its operations.
Unlimited Science, a psychedelics non-profit R&D organization, is collaborating with Johns Hopkins.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now